Effect of soy extract administration on losartan pharmacokinetics in healthy female volunteers

Annals of Pharmacotherapy

Volumn 43, Issue 6, 2009, Pages 1045-1049

  Wang, Guo ^a   Xiao, Chang Qiong ^a   Li, Zhi ^a   Guo, Dong ^a   Chen, Yao ^a   Fan, Lan ^a   Qian, Rong Hua ^a   Peng, Xiu Juan ^a   Hu, Dong Li ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Interaction; Isoflavone; Losartan; Pharmacokinetics; Soy extract

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; LOSARTAN; SOYBEAN PROTEIN;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MAXIMUM ALLOWABLE CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTI-ARRHYTHMIA AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CHINA; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; IMIDAZOLES; LOSARTAN; PLANT EXTRACTS; SOYBEANS; TANDEM MASS SPECTROMETRY; TETRAZOLES; TIME FACTORS; YOUNG ADULT;

EID: 67249115639     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L690     Document Type: Article

References (24)

1. Blumenthal M. Herbal sales down in mainstream market, up in natural food stores. HerbalGram 2002;55:60.
2. Anderson GD, Rosito G, Mohustsy MA, Elmer GW. Drug interaction potential of soy extract and panax ginseng. J Clin Pharmacol 2003;43:643-648 (Pubitemid 36613123)
3. Moon YJ, Wang XD, Morris ME. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicology In Vitro 2006;20:187-210. (Pubitemid 43087702)
4. Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004;22:2489-2503 (Pubitemid 41115408)
5. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-251 (Pubitemid 23191415)
6. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists: XI. Pharmacology of EXP3174 - an active metabolite of DuP753, an orally active anti-hypertensive agent. J Pharmacol Exp Ther 1990;255:211-217 (Pubitemid 20361505)
7. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995;58:641-649 (Pubitemid 26018849)
8. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993;35:290-297 (Pubitemid 23074055)
9. McCrea JB, Cribb A, Rushmore T, et al. Phenotypic and genotypic investigation of healthy volunteer deficient in conversion of losartan to its active metabolite E-3174. Clin Pharmacol Ther 1999;65:348-352 (Pubitemid 29142941)
10. Stearns RA, Chakravarty PK, Chen R, Chiu SH. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995;23:207-215
11. Kaukonen KM, Olkkola KT, Neuvonen PJ. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 1998;53:445-449 (Pubitemid 28154745)
12. Williamson KM, Patterson JH, McQueen RH, Adams KF, Pieper JA. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 1998;63:316-323 (Pubitemid 28182229)
13. Goldberg MR, Lo MW, Bradstreet TE, Ritter MA, Höglund P. Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an ATl-selective non-peptide angiotensin II receptor antagonist. Eur J Clin Pharmacol 1995;49:115-119
14. Kobayashi M, Takagi M, Fukumoto K, Kato R, Tanaka K, Ueno K. The Effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan. Drug Metab Pharmacokinet 2008;23:115-119
15. Wennerholm A, Nordmark A, Pihlsgard M, Mahindi M, Bertilsson L, Gustafsson LL. Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo. Eur J Clin Pharmacol 2006;62:539-546
16. Polinko M, Riffel K, Song H, Lo MW. Simultaneous determination of losartan and EXP3174 in human plasma and urine utilizing liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal 2003;33:73-84. (Pubitemid 37297519)
17. Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet 2005;44:797-814. (Pubitemid 41126929)
18. Zaidenstein R, Soback S, Gips M, et al. Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy volunteers. Ther Drug Monit 2001;23:369-373 (Pubitemid 32708920)
19. Meadowcroft AM, Williamson KM, Patterson JH, Hinderliter AL, Pieper JA. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999;39:418-424 (Pubitemid 29159832)
20. Huggett AC, Pridmore S, Malnoe A, Haschke F, Offord EA. Phytooestrogens in soy-based infant formula. Lancet 1997;350:815-816
21. Ueng YF, Chang YL, Oda Y, et al. In vitro and in vivo effects of naringin on cytochrome P450-dependent monooxygenase in mouse liver. Life Sci 1999;65:2591-2602
22. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in depression. J Pharmacol Exp Ther 2000;294:88-95. (Pubitemid 30434674)
23. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001;70:317-326
24. Roby CA, Anderson GD, Kantor ED, Dryer DA, Burstein AH. St. John's wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000;67:451-457 (Pubitemid 30327483)